Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C)

Brain and Behavior

Volumn 2, Issue 5, 2012, Pages 525-531

  Birerdinc, Aybike ^a,b   Afendy, Arian ^a   Stepanova, Maria ^a   Younossi, Issah ^a   Baranova, Ancha ^a,b   Younossi, Zobair M ^a  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

Author keywords

Depression; Hepatitis C; Interferon; Ribavirin; TGF 1; Th1 Th2 cytokines; Treatment

Indexed keywords

CYTOKINE; E1A ASSOCIATED P300 PROTEIN; MESSENGER RNA; PEGINTERFERON ALPHA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE R; REPRESSOR PROTEIN; RIBAVIRIN; STAT4 PROTEIN; THROMBOCYTE FACTOR 4; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ADULT; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; DEPRESSION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOWN REGULATION; EP300 GENE; FEMALE; GENE EXPRESSION PROFILING; HEPATITIS C; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PDGFA GENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PF4 GENE; PRIORITY JOURNAL; PRKRIR GENE; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAT4 GENE; TGF BETA1 GENE; TH1 CELL; TH2 CELL; TRAF6 GENE; UPREGULATION;

EID: 84882287082     PISSN: None     EISSN: 21623279     Source Type: Journal    
DOI: 10.1002/brb3.72     Document Type: Article

References (48)

1. Armstrong, G. L., A. Wasley, E. P. Simard, G. M. McQuillan, W. L. Kuhnert, and M. J. Alter 2006. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 144:705-714.
2. Barral-Netto, M., A. Barral, C. E. Brownell, Y. A. Skeiky, L. R. Ellingsworth, D. R. Twardzik, et al. 1992. Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 257:545-548.
3. Bondini, S., and Z. M. Younossi 2006. Non-alcoholic fatty liver disease and hepatitis C infection. Minerva Gastroenterol. Dietol. 52:135-143.
4. Capuron, L., and R. Dantzer 2003. Cytokines and depression: the need for a new paradigm. Brain Behav. Immun. 17 (Suppl. 1):S119-S124.
5. Capuron, L., and A. H. Miller 2004. Cytokines and psychopathology: lessons from interferon-alpha. Biol. Psychiatry 56:819-824.
6. Capuron, L., and A. Ravaud 1999. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N. Engl. J. Med. 340:1370.
7. Cejas, P. J., M. C. Walsh, E. L. Pearce, D. Han, G. M. Harms, D. Artis, et al. 2010. TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2. Blood 115:4750-4757.
8. Chen, T. Y., Y. S. Hsieh, T. T. Wu, S. F. Yang, C. J. Wu, G. J. Tsay, et al. 2007. Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. Transl. Res. 150:116-121.
9. Connor, T. J., and B. E. Leonard 1998. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 62:583-606.
10. Dan, A. A., L. M. Martin, C. Crone, J. P. Ong, D. W. Farmer, T. Wise, et al. 2006. Depression, anemia and health-related quality of life in chronic hepatitis C. J. Hepatol. 44:491-498.
11. Davis, G. L., M. J. Alter, H. El-Serag, T. Poynard, and L. W. Jennings 2010. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138:513-521.
12. Dieperink, E., S. B. Ho, P. Thuras, and M. L. Willenbring 2003. A prospective study of neuropsychiatric symptoms associated with interferon-a-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 44:104-112.
13. Fattovich, G., G. Giustina, S. Favarato, and A. Ruol 1996. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alpha interferon. J. Hepatol. 24:38-47.
14. Fontana, R. J., S. M. Schwartz, A. Gebremariam, A. S. Lok, and C. A. Moyer 2002. Emotional distress during interferon-α-2B and ribavirin treatment of chronic hepatitis C. Psychosomatics 43:378-385.
15. Garcia, E. P., L. A. Dowding, L. W. Stanton, and V. I. Slepnev 2005. Scalable transcriptional analysis routine-multiplexed quantitative real-time polymerase chain reaction platform for gene expression analysis and molecular diagnostics. J. Mol. Diagn. 7:444-454.
16. Groux, H., A. O'Garra, M. Bigler, M. Rouleau, S. Antonenko, J. E. de Vries, et al. 1997. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389:737-742.
17. Hauser, P., J. Khosla, H. Aurora, J. Laurin, M. A. Kling, J. Hill, et al. 2002. A prospective study of the incidence and open-label treatment of interferon induced major depressive disorder in patients with hepatitis C. Mol. Psychiatry 7:942-947.
18. Kuenzel, S., A. Till, M. Winkler, R. Häsler, S. Lipinski, S. Jung, et al. 2010. The nucleotide-binding oligomerization domain-like receptor NLRC5 is involved in IFN-dependent antiviral immune responses. J. Immunol. 184:1990-2000.
19. Laje, G., and F. J. McMahon 2011. Genome-wide association studies of antidepressant outcome: a brief review. Prog. Neuropsychopharmacol. Biol. Psychiatry 35:1553-1557.
20. Lee, K. M., and Y. K. Kim 2006. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int. Immunopharmacol. 6:1298-1304.
21. Lisak, R. P., J. A. Benjamins, B. Bealmear, L. Nedelkoska, B. Yao, S. Land, et al. 2007. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for glial and neural-related molecules in central nervous system mixed glial cell cultures: neurotrophins, growth factors and structural proteins. J. Neuroinflammation 18:30.
22. Maes, M. 1995. Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry 19:11-38.
23. Maes, M., E. Bosmans, E. Suy, C. Vandervorst, C. De Jonckheere, and J. Raus 1990. Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology 24:115-120.
24. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium. 2012. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry. doi: 10.1038/mp.2012.21
25. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, et al. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
26. Mauss, S., D. Hueppe, C. John, J. Goelz, R. Heyne, B. Moeller, et al. 2011. Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. J. Viral Hepat. 18:e81-e90. doi:10.1111/j.1365-2893.2010.01372.x
27. Mueller, A., A. Meiser, E. M. McDonagh, J. M. Fox, S. J. Petit, G. Xanthou, et al. 2008. CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3. J. Leukoc. Biol. 83:875-882.
28. Mulhall, B. P., and Z. Younossi 2005. Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J. Clin. Gastroenterol. 39:S23-S27.
29. Myint, A. M., and Y. K. Kim 2003. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med. Hypotheses 61:519-525.
30. Myint, A. M., B. E. Leonard, H. W. Steinbusch, and Y. K. Kim 2005. Th1, Th2, and Th3 cytokine alterations in major depression. J. Affect. Disord. 88:167-173.
31. Neumann-Haefelin, C., H. C. Spangenberg, H. E. Blum, and R. Thimme 2007. Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. World J. Gastroenterol. 13:4839-4847.
32. Prud'homme, G. J., and C. A. Piccirillo 2000. The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases. J. Autoimmun. 14:23-42.
33. Romagnani, P., L. Maggi, B. Mazzinghi, L. Cosmi, L. Lasagni, F. Liotta, et al. 2005. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J. Allergy Clin. Immunol. 116:1372-1379.
34. Saraiva, M., J. R. Christensen, M. Veldhoen, T. L. Murphy, K. M. Murphy, and A. O'Garra 2009. Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 31:209-219.
35. Schiepers, O. J., M. C. Wichers, and M. Maes 2005. Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 29:201-217.
36. Schmitt, E., P. Hoehn, C. Huels, S. Goedert, N. Palm, E. Rüde, et al. 1994. T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-beta. Eur. J. Immunol. 24:793-798.
37. Sharma, P., J. A. Marrero, R. J. Fontana, J. K. Greenson, H. Conjeevaram, G. L. Su, et al. 2007. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl. 13:1100-1108.
38. Tan, J., and A. S. Lok 2007. Update on viral hepatitis: 2006. Curr. Opin. Gastroenterol. 23:263-267.
39. Taylor, J. L., and S. E. Grossberg 1998. The effects of interferon-alpha on the production and action of other cytokines. Semin. Oncol. 25:23-29.
40. Taylor, A., J. Verhagen, K. Blaser, M. Akdis, and C. A. Akdis 2006. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 117:433-442.
41. Timm, J., and M. Roggendorf 2007. Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J. Gastroenterol. 13:4808-4817.
42. Valentine, A. D., C. A. Meyers, M. A. Kling, E. Richelson, and P. Hauser 1998. Mood and cognitive side effects of interferon-alpha therapy. Semin. Oncol. 25:39-47.
43. Van Thiel, D. H., L. Friedlander, N. De Maria, P. J. Molloy, R. J. Kania, and A. Colantoni 1998. Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease. Hepatogastroenterology 45:328-330.
44. Wynn, T. A., and L. Barron 2010. Macrophages: master regulators of inflammation and fibrosis. Semin. Liver Dis. 30:245-257.
45. Yirmiya, R. 2000. Depression in medical illness: the role of the immune system. West. J. Med. 173:333-336.
46. Younossi, Z., J. Kallman, and J. Kincaid 2007. The effects of HCV infection and management on health-related quality of life. Hepatology 45:806-816.
47. Younossi, Z. M., A. Baranova, A. Afendy, R. Collantes, M. Stepanova, G. Manyam, et al. 2009. Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin. Hepatology 49:763-774.
48. Zhang, L., H. Yi, X. P. Xia, and Y. Zhao 2006. Transforming growth factor-beta: an important role in CD4+CD25+ regulatory T cells and immune tolerance. Autoimmunity 39:269-276.